Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (2018)
16 slides from Coloplast A/s Class B's investor day presentation, 2018
Slide 1: Raising the bar for innovation in Chronic Care
Raising the bar for innovation in Chronic Care Coloplast Capital Markets Day 2018 Oliver Johansen, Senior Vice President, Global R&D
Slide 2: Innovation is the cornerstone of the company and we have recently launched several new products
Innovation is the cornerstone of the company and we have recently launched several new products in Chronic Care Superior products and innovation SenSura® Mio Convex SenSura® Mio Concave SpeediCath® Flex SpeediCath® Flex Coude Pro (US only) SenSura® Mio Hospital Assortment Brava® Protective Seal Brav
Slide 3: The SenSura Mio platform now addresses all body shapes
The SenSura® Mio platform now addresses all body shapes with different solutions for different challenges Real bodies have different 53% Regular fit 13% Inward fit 34% Outward fit shapes1 SenSura® Mio Flat SenSura® Mio Convex SenSura® Mio Concave 1) Source: Ostomy Life Study 2016, (n=4,235), (Data-o
Slide 4: SenSura Mio Concave solves an unmet need for people with outward body profiles
SenSura® Mio Concave solves an unmet need for people with outward body profiles Innovative features Clinical trials Two multicenter randomized Curved star shape clinical trials2 showed: Securing snug fit over bulges, hernias 83% and curves without creasing or folding with outward Superior body fit b
Slide 5: The launch of SenSura Mio Convex has demonstrated the impact of improved clinical performance
The launch of SenSura® Mio Convex has demonstrated the impact of improved clinical performance Clinical trials are not new to Coloplast but going forward our aim … ultimately leading to strong revenue growth is to improve clinical outcomes Sensura® Mio Convex & Group Bags & Plates, Revenue growth MA
Slide 6: Going forward we want to raise the standard of care through clinically superior products
Going forward we want to raise the standard of care through clinically superior products and innovation Raise the standard of care through clinically superior 4 innovation 3 Bring superior products faster to market with Innovation Excellence 2 Focus on Bigger Better Bolder products 1 Establish one G
Slide 7: In order to raise the standard of care we are investing in five themes
In order to raise the standard of care we are investing in five themes that will drive us forward Device technologies Agile product 3 Digital development 2 4 healthcare Enable effective 1 5 Market access and volume production value documentation • . Page 7
Slide 8: We have increased our R&D spend from 3% to 4% of sales
We have increased our R&D spend from 3% to 4% of sales Examples of strengthened R&D capabilities Coloplast has invested in further R&D resources # of R&D/Pilot FTEs External Pre-clinical partner- ships ~20% Medical Material affairs scientists Mechanical Process designers develop. FY 15/16 Today Sour
Slide 9: In Continence Care we have developed a new Bacteria Barrier Technology
3 DEVICE TECHNOLOGIES In Continence Care we have developed a new Bacteria Barrier Technology that reduces the risk of inserting bacteria Bacteria Barrier Technology (BBT) SpeediCath® Standard BBT performance Amount of viable e-coli bacteria measured on catheter • 42%1 of users are daily concerned wi
Slide 10: 30% of all ostomates experience mild to severe skin irritation or damage on a weekly basis
3 DEVICE TECHNOLOGIES 30% of all ostomates experience mild to severe skin irritation or damage on a weekly basis Product rationale Damaged peristomal skin • 30%1 of all users experience mild to severe skin irritation or damage on a weekly basis • Despite understanding the link between output on the
Slide 11: Within Ostomy Care we aim to significantly improve outcomes through improved adhesive and digital technologies
4 DIGITAL HEALTHCARE Within Ostomy Care we aim to significantly improve outcomes through improved adhesive and digital technologies Karen, Aged 52 • . Page 11
Slide 12: Our aspiration is to connect our products and services digitally
4 DIGITAL HEALTHCARE Our aspiration is to connect our products and services digitally to give users a much greater feeling of control and support better outcomes • . Page 12
Slide 13: We have strengthened our pre-clinical capabilities in order to improve outcomes
5 MARKET ACCESS AND VALUE DOCUMENTATION We have strengthened our pre-clinical capabilities in order to improve outcomes… Phases of clinical studies Strengthened pre-clinical capabilities 1 Pre-clinical 2 Pilot 3 Pivotal Pilot studies 4 Post-approval • . Page 13
Slide 14: Strong clinical evidence will allow us to achieve premiums and new categories linked to outcome
5 MARKET ACCESS AND VALUE DOCUMENTATION Strong clinical evidence will allow us to achieve premiums and new categories linked to outcome 1. Key payers interviewed in core markets 2. Key findings Possibility to get higher reimbursement prices if strong evidence is provided for… Germany UK France Impro
Slide 15: Going forward we want to raise the standard of care through clinically superior innovation
Going forward we want to raise the standard of care through clinically superior innovation Speed to market Premium reimbursement Line extensions within existing categories Launch into new/premium categories Shorter lead time and higher launch cadence Longer lead times due to technology developme
Slide 16: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /